bioAffinity Technologies Inc. stocks have been trading up by 10.23 percent following promising news on its cancer diagnostics progress.
Click Here for a Millionaire's POV on Trading BIAF
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Sales of bioAffinity Technologies’ CyPath Lung diagnostic test more than doubled year-over-year through Q3 2026, with tests performed increasing from 775 to over 1,620 and an 89% rise in ordering physician offices.
- The company received a Hong Kong patent for CyPath Lung, complementing an existing China patent and expanding IP protection for its noninvasive lung cancer diagnostic platform across Asia.
- A nationwide federal healthcare distribution deal with veteran‑owned AvMEDICAL targets wider CyPath Lung access across the U.S. Department of Veterans Affairs and other federal healthcare systems.
- bioAffinity Technologies will present positive clinical, economic, and veteran‑focused CyPath Lung data at the 2026 NAVREF Annual Conference, including an ongoing 2,000‑patient veteran/military longitudinal study and real‑world cases.
- BIAF regained compliance with Nasdaq listing requirements for its common stock and warrants, removing immediate delisting risk and allowing continued trading on the Nasdaq Capital Market.
Live Update At 08:32:18 EDT: On Thursday, October 08, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 10.23%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
BIAF has been trading like a classic low‑float biotech momentum name. Over the past few weeks, bioAffinity Technologies has swung from a high near $12 on 2026/09/18 down into the mid‑$6s by 2026/10/07. That is a sharp round‑trip, and it tells traders one thing clearly: BIAF remains highly sensitive to headlines and order flow.
The Hong Kong patent news in mid‑September sent BIAF up about 59% on heavy volume, but the daily chart now shows a steady fade from the $8–$12 area into a tight band around $6–$6.50. The recent candles between 2026/09/29 and 2026/10/07 show lower highs and support forming around $6, a key line for short‑term traders.
More Breaking News
- LRHC Stock Slides As Traders Zero In On Risky Fundamentals
- SXTC Stock Volatility Spikes As Traders Eye Deep Value
- FLYE Stock Rockets On Heavy Volume As Traders Pile In
- BYAH Stock Pulls Back As Volatility Grabs Trader Attention
Under the hood, bioAffinity Technologies is still an early‑stage commercial story. Revenue sits around $6.1M, but margins are deeply negative, with EBIT margin near ‑259%. BIAF is burning cash, posting roughly ‑$3.2M in operating cash flow in the latest quarter, funded mainly by stock issuance. Debt is modest and the current ratio around 1.4 shows some breathing room, yet the business must keep scaling CyPath Lung sales to narrow losses. For traders, that tug‑of‑war between strong top‑line growth and heavy red ink explains the volatility on the chart.
Why Traders Are Watching BIAF’s CyPath Lung Momentum
This latest news flow around bioAffinity Technologies is all about traction. Through Q3 2026, CyPath Lung test volumes more than doubled year‑over‑year, from 775 to over 1,620. That is not just a rounding error. For a small diagnostics player like BIAF, that kind of growth hints at a real shift from pilot use to broader clinical adoption. An 89% jump in ordering physician offices and a 48% rise in utilization from existing prescribers backs up that view.
Traders watching BIAF are not only tracking numbers; they are watching channels. The nationwide federal distribution agreement with veteran‑owned AvMEDICAL opens the door to the VA and other federal systems. If even a slice of the at‑risk veteran population moves onto CyPath Lung, test volumes for bioAffinity Technologies could scale far beyond today’s base. That kind of contract often acts as a medium‑term catalyst, feeding spikes whenever new VA‑related milestones hit the tape.
On the intellectual property side, the Hong Kong patent for CyPath Lung, layered on top of an existing China patent, strengthens BIAF’s position across Asia. When that Hong Kong patent headline landed, the stock ripped roughly 59% on massive volume. That single move told traders exactly how the market is pricing BIAF’s optionality: every IP or commercialization win can trigger fast, outsized swings.
Add in upcoming presentations at the 2026 NAVREF conference, including data from a 2,000‑patient veteran and military study plus cost‑saving analyses, and BIAF suddenly has multiple narrative drivers. For momentum traders, this is the setup: improving fundamentals, expanding IP, a new federal channel, and a tape that has already proven it can move.
Conclusion
For active traders, bioAffinity Technologies sits at the intersection of story and stats. BIAF just cleared a major overhang by regaining full Nasdaq compliance for both its common stock and warrants, taking delisting risk off the table for now. That stabilizes the platform for trading and lets management focus on turning CyPath Lung into a meaningful revenue engine.
At the same time, the financials remind everyone what this is: a high‑risk, high‑reward early commercial biotech. Revenue is ramping quickly, but losses remain steep and cash burn is real. Future fundraises are a live topic whenever you look at a name like BIAF. That is why disciplined chart work matters. The recent base around $6 on the daily suggests a key battleground. A break below that zone can change the whole tone, while a push back through the $7–$8 band would show fresh momentum returning.
The expanding VA and federal footprint via AvMEDICAL, the Asia patent wall, and the NAVREF data stream give BIAF a steady pipeline of potential catalysts. For traders who thrive on volatility, that combination often creates opportunity. As Tim Sykes loves to say, “The market doesn’t care about your opinion, only your plan and your discipline.” In the same spirit of focusing on process over ego, it’s crucial to treat each BIAF trade as a learning rep. As Tim Bohen, lead trainer with StocksToTrade says, “The best way to learn is by tracking trades, wins, losses, and lessons learned. Every trade has something to teach.” With BIAF, the plan has to start with risk control, tight levels, and respect for how fast this stock has already proven it can move—both up and down.
This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.